Key Opinion Leader Event
Jun 9, 2021
Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter.